607 related articles for article (PubMed ID: 8639850)
1. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
2. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
3. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD
Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission.
Guerrasio A; Rosso C; Martinelli G; Lo Coco F; Pampinella M; Santoro A; Lanza C; Allione B; Resegotti L; Saglio G
Br J Haematol; 1995 Jun; 90(2):364-8. PubMed ID: 7794758
[TBL] [Abstract][Full Text] [Related]
5. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
[TBL] [Abstract][Full Text] [Related]
6. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
Kwong YL; Chan V; Wong KF; Chan TK
Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
Tobal K; Yin JA
Blood; 1996 Nov; 88(10):3704-9. PubMed ID: 8916934
[TBL] [Abstract][Full Text] [Related]
8. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia.
Miyamoto T; Nagafuji K; Harada M; Eto T; Fujisaki T; Kubota A; Akashi K; Mizuno S; Takenaka K; Kanaji T
Br J Haematol; 1995 Sep; 91(1):132-8. PubMed ID: 7577620
[TBL] [Abstract][Full Text] [Related]
10. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
[TBL] [Abstract][Full Text] [Related]
11. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Harada M; Niho Y
Leuk Lymphoma; 1997 Mar; 25(1-2):69-75. PubMed ID: 9130615
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears.
Tsukamoto N; Karasawa M; Tanaka Y; Yokohama A; Uchiumi H; Matsushima T; Murakami H; Nojima Y
Int J Hematol; 2003 Nov; 78(4):362-9. PubMed ID: 14686496
[TBL] [Abstract][Full Text] [Related]
13. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.
Era T; Asou N; Kunisada T; Yamasaki H; Asou H; Kamada N; Nishikawa S; Yamaguchi K; Takatsuki K
Genes Chromosomes Cancer; 1995 May; 13(1):25-33. PubMed ID: 7541640
[TBL] [Abstract][Full Text] [Related]
14. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
[TBL] [Abstract][Full Text] [Related]
15. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
[TBL] [Abstract][Full Text] [Related]
16. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
Miyamoto T; Weissman IL; Akashi K
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7521-6. PubMed ID: 10861016
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
[TBL] [Abstract][Full Text] [Related]
18. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
[TBL] [Abstract][Full Text] [Related]
19. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
20. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]